Clinical Impact of Systemic Treatment Choices Made in Current Practice in Elderly Patients with Atopic Dermatitis
DOI:
https://doi.org/10.2340/actadv.v105.44174Keywords:
Aged, atopic dermatitis, therapeutics, observational studyAbstract
Increasing life expectancy will lead to more elderly people with atopic dermatitis; however, analyses of the impact of atopic dermatitis therapy on the elderly are lacking. This prospective, multicentre observational study assessed the effect of treatment choice on the efficacy of atopic dermatitis therapies in patients with atopic dermatitis aged ≥ 65 years vs < 65 years in France. Clinical endpoints assessed included changes in Eczema Area and Severity Index scores, atopic dermatitis-related hospitalizations, and quality of life. Between December 2020 and October 2024, 679 patients were included in the study (≥65 years: n = 83; < 65 years: n = 596). At baseline, most patients had moderate/severe atopic dermatitis. Biological therapy was the most common treatment initiated at the enrollment visit (≥ 65 years: 72.3%; < 65 years: 54.0%). At 12 months, the mean Eczema Area and Severity Index score decreased similarly in both groups (p = 0.845), from 17.6 ±9.6 to 3.7 ± 5.2 for patients aged ≥ 65 years and from 18.4 ±12.3 to 4.3 ± 5.5 for those aged < 65 years. The reduction in number of atopic dermatitis-related hospitalizations was significant and similar in both groups, and quality of life improved across all areas. Overall, results suggest that therapeutic choices made by dermatologists have a positive impact on elderly patients with atopic dermatitis.
Downloads
References
Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol 2021; 184: 304–309. DOI: https://doi.org/10.1111/bjd.19580
de Bruin-Weller M, Gadkari A, Auziere S, Simpson EL, Puig L, Barbarot S, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol 2020; 34: 1026–1036. DOI: https://doi.org/10.1111/jdv.16003
Bylund S, Von Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol 2020; 100: 320–329. DOI: https://doi.org/10.2340/00015555-3510
Kim JP, Chao LX, Simpson EL, Silverberg JI. Persistence of atopic dermatitis (AD): a systematic review and meta-analysis. J Am Acad Dermatol 2016; 75: 681–687.e11. DOI: https://doi.org/10.1016/j.jaad.2016.05.028
von Kobyletzki LB, Bornehag CG, Breeze E, Larsson M, Boman Lindström C, Svensson Å. Factors associated with remission of eczema in children: a population-based follow-up study. Acta Derm Venereol 2014; 94: 179–184. DOI: https://doi.org/10.2340/00015555-1681
Ellis CN, Mancini AJ, Paller AS, Simpson EL, Eichenfield LF. Understanding and managing atopic dermatitis in adult patients. Semin Cutan Med Surg 2012; 31: S18–22. DOI: https://doi.org/10.1016/j.sder.2012.07.006
Nishioka K. Atopic eczema of adult type in Japan. Australas J Dermatol 1996; 37: S7–9. DOI: https://doi.org/10.1111/j.1440-0960.1996.tb01088.x
Tanei R, Hasegawa Y. Atopic dermatitis in older adults: a viewpoint from geriatric dermatology. Geriatr Gerontol Int 2016; 16: 75–86. DOI: https://doi.org/10.1111/ggi.12771
Howell AN, Ghamrawi RI, Strowd LC, Feldman SR. Pharmacological management of atopic dermatitis in the elderly. Expert Opin Pharmacother 2020; 21: 761–771. DOI: https://doi.org/10.1080/14656566.2020.1729738
Salava A, Rieppo R, Lauerma A, Salo V. Age-dependent distribution of atopic dermatitis in primary care: a nationwide population-based study from Finland. Acta Derm Venereol 2022; 102: adv00738. DOI: https://doi.org/10.2340/actadv.v102.2287
Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 2013; 132: 1132–1138. DOI: https://doi.org/10.1016/j.jaci.2013.08.031
Pollyn-Millot C, Maccari F, Perrot JL, Reguiai Z, Boulard C, Bécherel PA, et al. Clinical characteristics and therapeutic management of atopic dermatitis in elderly patients compared with young adult patients: a prospective multicentre study. Acta Derm Venereol 2024; 104: adv40420. DOI: https://doi.org/10.2340/actadv.v104.40420
Lam M, Zhu JW, Maqbool T, Adam G, Tadrous M, Rochon P, et al. Inclusion of older adults in randomized clinical trials for systemic medications for atopic dermatitis: a systematic review. JAMA Dermatol 2020; 156: 1240–1245. DOI: https://doi.org/10.1001/jamadermatol.2020.2940
Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 2012; 26: 1176–1193. DOI: https://doi.org/10.1111/j.1468-3083.2012.04636.x
Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717–2744. DOI: https://doi.org/10.1111/jdv.16892
Becherel PA, Reguiai Z, Fougerousse AC, Perrot JL, Begon E, Thomas-Beaulieu D, et al. Compared burden of psoriasis, atopic dermatitis, hidradenitis suppurativa, and chronic urticaria: baseline characteristics of the patients included in the OMCCI cohort – A French, prospective multicenter study of chronic inflammatory dermatoses. Dermatology 2024; 240: 702–712. DOI: https://doi.org/10.1159/000540250
Halioua B, Corgibet F, Taieb C, Thenie C, Veniard C, Noel M, et al. Therapeutic inertia in the management of patients with inadequately controlled atopic dermatitis. J Eur Acad Dermatol Venereol 2022; 36: e817–e818. DOI: https://doi.org/10.1111/jdv.18303
de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 2018; 178: 1083–1101. DOI: https://doi.org/10.1111/bjd.16156
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335–2348. DOI: https://doi.org/10.1056/NEJMoa1610020
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287–2303. DOI: https://doi.org/10.1016/S0140-6736(17)31191-1
Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021; 184: 437–449. DOI: https://doi.org/10.1111/bjd.19574
Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397: 2169–2181. DOI: https://doi.org/10.1016/S0140-6736(21)00589-4
Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156: 1333–1343. DOI: https://doi.org/10.1001/jamadermatol.2020.3260
Thyssen JP, Werfel T, Barbarot S, Hunter HJA, Pierce E, Sun L, et al. Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial. J Dermatolog Treat 2023; 34: 2190430. DOI: https://doi.org/10.1080/09546634.2023.2190430
Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat 2022; 33: 1521–1530. DOI: https://doi.org/10.1080/09546634.2020.1839008
Lio PA, Simpson EL, Han G, Soung J, Ball S, Sun L, et al. Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy. J Dermatolog Treat 2022; 33: 2057–2062. DOI: https://doi.org/10.1080/09546634.2021.1914308
Wollenberg A, Nakahara T, Maari C, Peris K, Lio P, Augustin M, et al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 phase 3 randomized trial. J Eur Acad Dermatol Venereol 2021; 35: 1543–1552. DOI: https://doi.org/10.1111/jdv.17278
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med 2021; 384: 1101–1112. DOI: https://doi.org/10.1056/NEJMoa2019380
Shi VY, Bhutani T, Fonacier L, Deleuran M, Shumack S, Valdez H, et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol 2022; 87: 351–358. DOI: https://doi.org/10.1016/j.jaad.2022.04.009
Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397: 2151–2168. DOI: https://doi.org/10.1016/S0140-6736(21)00588-2
Thyssen JP, Thaçi D, Bieber T, Gooderham M, de Bruin-Weller M, Soong W, et al. Upadacitinib for moderate-to-severe atopic dermatitis: stratified analysis from three randomized phase 3 trials by key baseline characteristics. J Eur Acad Dermatol Venereol 2023; 37: 1871–1880. DOI: https://doi.org/10.1111/jdv.19232
Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020; 396: 255–266. DOI: https://doi.org/10.1016/S0140-6736(20)30732-7
Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156: 863–873. DOI: https://doi.org/10.1001/jamadermatol.2020.1406
Silverberg JI, Lynde CW, Abuabara K, Patruno C, de Benedetto A, Zhang H, et al. Efficacy and safety of dupilumab maintained in adults ≥ 60 years of age with moderate-to-severe atopic dermatitis: analysis of pooled data from four randomized clinical trials. Am J Clin Dermatol 2023; 24: 469–483. DOI: https://doi.org/10.1007/s40257-022-00754-4
Hren MG, Khattri S. Use of systemic Janus kinase inhibitors for dermatologic indications in the elderly: a retrospective study of 67 cases. J Am Acad Dermatol 2024; 90: 816–819. DOI: https://doi.org/10.1016/j.jaad.2023.11.055
Piscazzi F, Gargiulo L, Ibba L, Valenti M, Facheris P, Costanzo A, et al. Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients. J Dermatolog Treat 2023; 34: 2245510. DOI: https://doi.org/10.1080/09546634.2023.2245510
Reguiai Z, Becherel PA, Fougerousse AC, Chaby G, Perrot JL, Begon E, et al. Janus kinase inhibitors for the treatment of atopic dermatitis: real-life data on efficacy and safety in light of the pharmacovigilance risk assessment committee recommended measures. J Eur Acad Dermatol Venereol 2023; 37: e1307–e1309. DOI: https://doi.org/10.1111/jdv.19302
Published
How to Cite
License
Copyright (c) 2025 Clara Mathieu, François Maccari, Jean-Luc Perrot, Ziad Reguiai, Claire Boulard, Pierre-André Becherel, Anne-Claire Fougerousse, Laure Mery-Bossard, Domitille Thomas-Beaulieu, Diane Pourchot, Claire Poreaux, Charlotte Fite, Ines Zaraa, Edouard Begon, Anne-Laure Liegeon, Caroline Jacobzone , Charline Garcia, Charlotte Lepelley Dupont, Daphné Denis, Matthieu Levavasseur, Anne-Claire Bing, Anne-Sophie Dillies, Alexandra Patchinsky, Rima Mohty, Dalila Simonian, Josiane Parier, Guillaume Chaby
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
